uniQure NV CEO Matthew Kapusta Sells 27,904 Shares
uniQure NV (NASDAQ:QURE), a company specializing in gene therapy, has reported a significant insider transaction. CEO and Managing Director Matthew Kapusta sold 27,904 shares of the company on February 26, 2024, according to a recent SEC filing.uniQure NV is at the forefront of developing innovative gene therapies for patients with severe genetic diseases and conditions. The company's advanced research and development efforts are focused on delivering potentially curative treatments that can fundamentally change patients' lives.Matthew Kapustas recent transaction is part of a series of sales over the past year, during which the insider has sold a total of 30,425 shares and has not made any purchases of the company's stock.The insider transaction history for uniQure NV shows a trend of insider sales, with 20 insider sells recorded over the past year and no insider buys during the same period.
On the valuation front, uniQure NV shares were trading at $6.35 on the day of the insider's recent sale, giving the company a market cap of approximately $319.859 million.The stock's price-to-GF-Value ratio stands at 1.58, indicating that uniQure NV is significantly overvalued based on its GF Value of $4.02. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which takes into account historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates from Morningstar analysts.
Investors and analysts often monitor insider transactions as they can provide insights into the insider's perspective on the company's current valuation and future prospects. The recent sale by the insider at uniQure NV may attract attention from the market as stakeholders evaluate the implications of this insider activity.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
